Document is current
Any future updates will be listed below
-
Authors
Fraslin, Aldéric
Colrat, Florian
Karimi, Maryam
Bonastre, Julia
Groussard, Karine
Teitsson, Siguroli
Prudent, Alexis
Branchoux, Sébastien
Radvanyi, François
Benhamou, Simone
Allory, Yves
Lebret, Thierry
-
Funding
Funding for this research was provided by:
French Ministry of Research
National League against Cancer
Institute of Research in Public Health - National Institute of Health and Medical Research
Bristol Myers Squibb
- License Information
-
More Information
Article History
Received: 12 August 2024
Accepted: 17 April 2025
First Online: 12 May 2025
Declarations
:
: The study was conducted in accordance with International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and applicable regulatory requirements. The COBLAnCE study was approved by the relevant French ethics committee (Comité de Protection des Personnes Ile de France VII; approval n° CO-12-001), the French data protection authority (Commission Nationale de l’Informatique et des Libertés; approval n° DR-2012-441) and the French biological tissue collection authority (approval n° DR-2012-1486). Each patient enrolled provided written informed consent. The current study did not require additional approval.
: Not applicable.
: Julia Bonastre reports consulting fees for scientific advisory board from Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Janssen and Roche. Yves Allory reports fees to Institut Curie from Bristol Myers Squibb and Merck Sharp & Dome. Thierry Lebret reports personal fees from Bristol Myers Squibb and Ferring. Simone Benhamou reports personal fees from AstraZeneca. Florian Colrat, Siguroli Teitsson, Alexis Prudent and Sébastien Branchoux are employees of Bristol Myers Squibb. Aldéric Fraslin, Maryam Karimi, Karine Groussard and François Radvanyi declare no conflicts of interest.
